Jackass: Best and Last Audience Reviews: A Bittersweet but Laugh-Out-Loud Funny Goodbye Link to Jackass: Best and Last Audience Reviews: A Bittersweet but Laugh-Out-Loud Funny Goodbye Jackass: Best ...

Australia toughens kids' social media ban, doubles potential penalties for tech firms Australia said on Saturday it would double the maximum penalty it can impose on tech firms found to have failed to ...

Trying to keep up with the latest in pop culture? We’ve got you covered. The Pop Culture Happy Hour podcast helps you find the best new binge-worthy tv shows, movies, music, and videogames. Join hosts ...

David Eby says he has been asked by the federal government to be available in early July for an announcement of a finalized memorandum of understanding. The popular park will be closed from June 20 to ...

Ralph welcomes journalist and author Megan Greenwell to discuss her book “Bad Company: Private Equity and the Death of the American Dream.” Then, Ralph speaks to James Zogby (co-founder and president ...

Exploring the biggest questions of our time with the help of the world's greatest thinkers. Host Manoush Zomorodi inspires us to learn more about the world, our communities, and most importantly, ...

One Hour Heating & Air Conditioning is a franchise-based HVAC service provider operating across the U.S. The company offers heating and cooling system installation, repair and maintenance services ...

Alexis Ohanian on women's sport, Shadow banning, Malory Towers on stage, Margo from Race Across the World Serena Williams' husband on his decision to invest in women's sports.

Genome-wide association and fine-mapping analyses of type 1 diabetes (T1D) identify multiple genetic risk signals. Furthermore, a machine learning model, T1GRS, improves the prediction of T1D in ...

The most visible spokesperson for the families of Israeli hostages in Gaza discusses her memoir, “When We See You Again,” and the unending pain of her son’s captivity and murder. The podcaster ...

A compilation of the latest Witness History programmes.

Prior authorization remains a major barrier to biologic access in AD. Dr Chuck Vega covers denial rates, appeal outcomes, and the clinical data that make the fight worthwhile.